Link Between Breast Cancer Hormone Receptor Status And Risk Of A Second Primary Tumor
Women with hormone receptor (HR) negative first tumors have twice as much risk for developing a second breast cancer as women with HR-positive tumors, according to a study published online July 9 in the Journal of the National Cancer Institute. Christina A. Clarke, Ph.D., of the Northern California Cancer Center in Fremont, Calif.
source : www.medicalnewstoday.com
How DUMB are YOU?!
Do your friends think you are stupid? Take the challenge and prove them wrong!
Beat your friends on IQ Challenge!
Take the 10-Minute IQ Challenge today. Prove to your friends that you aren't stupid after all!
Wal-Mart $1000 Gift Card in 5 min
$1000 Wal-Mart gift card with just a simple survey!
5min survey = $1000 Best Buy Card
Take a quick 5 min survey and get a chance for a $1000 Best Buy Gift Card!
Which AVATAR Character are You?!
Did you watch Avatar? Are you Jake, Neytiri, or the Colonel? Find out which Avatar Character you really are!
Do your friends think you are stupid? Take the challenge and prove them wrong!
Beat your friends on IQ Challenge!
Take the 10-Minute IQ Challenge today. Prove to your friends that you aren't stupid after all!
Wal-Mart $1000 Gift Card in 5 min
$1000 Wal-Mart gift card with just a simple survey!
5min survey = $1000 Best Buy Card
Take a quick 5 min survey and get a chance for a $1000 Best Buy Gift Card!
Which AVATAR Character are You?!
Did you watch Avatar? Are you Jake, Neytiri, or the Colonel? Find out which Avatar Character you really are!
Related News:
- European Medicines Agency Makes Recommendations To Minimise Risk Of…
- $16 Million Grant From State Stem Cell Agency To Speed Research Of…
- Book and Media Reviews: American Psychiatric Publishing Textbook of…
- Robotic Surgery Expert Dr. David B. Samadi Discusses The Benefits Of…
- UM Doctor To Lead Clinical Trial For ALS
- Migraine as inspiration
- Impax Pharmaceuticals Reports Positive Results of Phase II Trial of…
- Analysis of TB treatment studies identifies gaps in guidelines
- Weighing costs, benefits of HIV treatments
- Strativa Pharmaceuticals’ Development Partner, BioAlliance Pharma, Presents Phase III Study Results Of Miconazole Lauriad(R)
Details :
Submited at Saturday, July 11th, 2009 at 8:00 am on Endocrinology by Gillan
Comment RSS 2.0 - leave a comment - trackback
Leave Comment Here...
















